MetaCap

IDEAYA Biosciences (IDYA) vs Prestige Consumer Healthcare (PBH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prestige Consumer Healthcare (PBH) has outperformed IDEAYA Biosciences (IDYA) over the past year, losing 16.5% versus a loss of 24.8%. Over five years, IDYA leads with a +7.3% price change compared with -12.0% for PBH. IDEAYA Biosciences is the larger company by market cap ($2.47 billion vs $2.35 billion), about 1.1 times the size.

Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -52.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%PBH-16.48%
+28%-1%-30%
Nov 21, 20251 yearNov 20, 2026
IDYA+10.08%PBH-14.81%
+111%+21%-69%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus PBH key metrics
MetricIDYAPBH
Share price$25.56$49.63
Market cap$2.47B$2.35B
1-day change-2.33%+0.06%
YTD return-26.06%-19.55%
1-year return-24.80%-16.48%
5-year return+7.35%-12.02%
P/E ratio (TTM)—15.32
Forward P/E—9.76
EPS (TTM)$-4.50$3.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M$1.09B
Revenue growth (YoY)+3024.43%-4.31%
Net income (latest FY)$-113.70M$190.30M
Gross margin—54.71%
Operating margin-72.84%28.42%
Net margin-51.99%17.48%
52-week high$42.68$71.07
52-week low$25.46$41.77
Distance from 52-week high-40.11%-30.17%
Analyst consensusstrong_buybuy
Avg. price target upside+98.32%+33.39%
Average volume933.58K583.25K
Shares outstanding96.69M47.40M
Employees145890
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
  • IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -4.31%).

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

IDYA vs PBH FAQ

Which is bigger, IDEAYA Biosciences or Prestige Consumer Healthcare?

IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $2.47B compared with $2.35B for Prestige Consumer Healthcare (PBH).

Which stock has performed better over the past year, IDYA or PBH?

PBH returned -16.48% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and Prestige Consumer Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons